MA30061B1 - Preparation solide - Google Patents

Preparation solide

Info

Publication number
MA30061B1
MA30061B1 MA31045A MA31045A MA30061B1 MA 30061 B1 MA30061 B1 MA 30061B1 MA 31045 A MA31045 A MA 31045A MA 31045 A MA31045 A MA 31045A MA 30061 B1 MA30061 B1 MA 30061B1
Authority
MA
Morocco
Prior art keywords
insulin sensitizer
solid preparation
active component
coated
sensitizer
Prior art date
Application number
MA31045A
Other languages
English (en)
Inventor
Kenichiro Kiyoshima
Kenji Nakamura
Tetsuya Kawano
Masafumi Misaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37951491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30061(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30061B1 publication Critical patent/MA30061B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention vise à fournir une préparation solide qui contient un sensibilisateur à l'insuline et un composant actif autre qu'un sensibilisateur à l'insuline et manifeste une conduite de dissolution d'un sensibilisateur à l'insuline semblable à celle d'un sensibilisateur à l'insuline provenant d' "une préparation solide contenant seulement un sensibilisateur à l'insuline à titre de composant actif". La préparation solide comprend "une partie contenant des particules enrobées dans laquelle les particules contenant un sensibilisateur à l'insuline sont enrobées avec du lactose ou un alcool de sucre" et "une partie contenant un composant actif autre qu'un sensibilisateur à l'insuline".
MA31045A 2005-12-22 2008-06-18 Preparation solide MA30061B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005370375 2005-12-22

Publications (1)

Publication Number Publication Date
MA30061B1 true MA30061B1 (fr) 2008-12-01

Family

ID=37951491

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31045A MA30061B1 (fr) 2005-12-22 2008-06-18 Preparation solide

Country Status (24)

Country Link
US (1) US8071130B2 (fr)
EP (1) EP1962811B1 (fr)
JP (1) JP5179363B2 (fr)
KR (1) KR20080080126A (fr)
CN (1) CN101384251B (fr)
AR (1) AR058605A1 (fr)
AU (1) AU2006328328B2 (fr)
BR (1) BRPI0620020A2 (fr)
CA (1) CA2633149C (fr)
CR (1) CR10032A (fr)
ES (1) ES2576258T3 (fr)
GE (1) GEP20115245B (fr)
HR (1) HRP20160679T1 (fr)
IL (1) IL191774A0 (fr)
MA (1) MA30061B1 (fr)
MY (1) MY149306A (fr)
NO (1) NO20083104L (fr)
NZ (1) NZ569071A (fr)
PE (1) PE20110019A1 (fr)
RU (1) RU2426530C2 (fr)
TW (1) TWI384985B (fr)
UA (1) UA91729C2 (fr)
WO (1) WO2007072992A2 (fr)
ZA (1) ZA200805147B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019669B1 (fr) 2006-05-23 2011-11-23 Takeda Pharmaceutical Company Limited Préparation orale comprenant de la pioglitazone
BRPI0807453B8 (pt) 2007-02-01 2021-05-25 Takeda Pharmaceuticals Co preparação sólida
WO2009028487A1 (fr) * 2007-08-27 2009-03-05 Asahi Kasei Chemicals Corporation Procédé de fabrication de comprimés contenant à la fois de cellulose cristalline et des granulés
NZ594738A (en) * 2009-01-23 2013-11-29 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
MX337603B (es) * 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
CN101804056A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 盐酸吡格列酮、格列美脲的复方片剂及制备方法
EP2611434A1 (fr) 2010-09-01 2013-07-10 Lupin Limited Composition pharmaceutique contenant de la metformine et de la pioglitazone
EP2618827B1 (fr) * 2010-09-21 2021-06-02 Intekrin Therapeutics, Inc. Compositions pharmaceutiques solides antidiabétiques
FR2966828B1 (fr) * 2010-11-02 2012-12-28 Roquette Freres Poudre de polysaccharide et de polyol, comprimable et de haute viscosite
WO2013034174A1 (fr) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Préparations solides de pioglitazone et de glimépiride
EP2753309B1 (fr) * 2011-09-08 2020-01-01 Hexal AG Composition pharmaceutique pour l'administration orale dotée d' une statine
BR112014008744A2 (pt) 2011-10-21 2017-04-18 Takeda Pharmaceuticals Co preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN102641280A (zh) * 2012-04-23 2012-08-22 重庆康刻尔制药有限公司 一种盐酸吡格列酮格列美脲组合药物、片剂及其应用
CA2979033A1 (fr) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
KR101782119B1 (ko) * 2016-02-01 2017-10-23 주식회사 한독 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
CN111410687B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种长效glp-1化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3152978B2 (ja) 1991-12-17 2001-04-03 塩野義製薬株式会社 二層錠およびその製造方法
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
AP1600A (en) 1997-06-18 2006-04-28 Smithkline Beecham Plc Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US7399485B1 (en) 1998-07-28 2008-07-15 Takeda Pharmaceutical Company Limited Rapidly Disintegrable solid preparation
BR9915285A (pt) * 1998-11-12 2001-08-07 Smithkline Beecham Plc Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético
EP1140145B2 (fr) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Nouvelles formulations d'agonistes de l'exendine et modes d'administration
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
AU2001294192A1 (en) * 2000-10-06 2002-04-22 Takeda Chemical Industries Ltd. Solid preparations
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
RU2177318C1 (ru) 2000-12-21 2001-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с антидиабетическим действием и способ ее получения
US20040147584A2 (en) * 2001-12-05 2004-07-29 Aventis Pharma S.A. 1,3-diarylprop-2-en-1-ones, compositions containing them and use thereof
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1552832A1 (fr) 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
NZ541749A (en) 2003-01-29 2009-06-26 Takeda Pharmaceutical Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
WO2004069229A1 (fr) * 2003-02-05 2004-08-19 Ipca Laboratories Limited Medicaments antidiabetiques a double liberation et procede de production de ceux-ci
WO2004091587A1 (fr) * 2003-04-17 2004-10-28 Ipca Laboratories Limited Liberation multiple de medicaments anti-diabete et procede de production associe
MXPA05013147A (es) 2003-06-06 2006-03-17 Takeda Pharmaceutical Preparacion solida.
BRPI0412009A (pt) 2003-06-27 2006-08-15 Reddy Research Foundation composições compreendendo balaglitazona e outros compostos antidiabéticos
WO2005009407A2 (fr) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Formulations pharmaceutiques d'olanzapine administrees par voie orale
HUE028576T2 (en) * 2003-10-31 2016-12-28 Takeda Pharmaceuticals Co Solid preparation containing pioglitazone, glimepiride and polyoxyethylene sorbitan fatty acid ester
JP4361461B2 (ja) * 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
WO2005102290A1 (fr) * 2004-04-22 2005-11-03 Ranbaxy Laboratories Limited Compositions pharmaceutiques formees d'un biguanide et d'une sulfonyluree

Also Published As

Publication number Publication date
CA2633149A1 (fr) 2007-06-28
IL191774A0 (en) 2008-12-29
US20090028939A1 (en) 2009-01-29
ZA200805147B (en) 2010-05-26
KR20080080126A (ko) 2008-09-02
WO2007072992A2 (fr) 2007-06-28
CN101384251A (zh) 2009-03-11
MY149306A (en) 2013-08-30
ES2576258T3 (es) 2016-07-06
AR058605A1 (es) 2008-02-13
HRP20160679T1 (hr) 2016-07-15
BRPI0620020A2 (pt) 2011-10-25
EP1962811B1 (fr) 2016-04-27
CA2633149C (fr) 2015-06-30
EP1962811A2 (fr) 2008-09-03
JP5179363B2 (ja) 2013-04-10
NZ569071A (en) 2011-01-28
TW200731971A (en) 2007-09-01
JP2009520681A (ja) 2009-05-28
GEP20115245B (en) 2011-06-27
CN101384251B (zh) 2014-09-03
WO2007072992A3 (fr) 2007-12-06
UA91729C2 (ru) 2010-08-25
US8071130B2 (en) 2011-12-06
RU2008130074A (ru) 2010-01-27
PE20110019A1 (es) 2011-01-27
CR10032A (es) 2008-10-03
TWI384985B (zh) 2013-02-11
AU2006328328B2 (en) 2012-08-30
NO20083104L (no) 2008-09-19
AU2006328328A1 (en) 2007-06-28
RU2426530C2 (ru) 2011-08-20

Similar Documents

Publication Publication Date Title
MA30061B1 (fr) Preparation solide
TN2010000073A1 (fr) Compositon pharmaceutique contenant un derive de benzene substitue par glucopyranosyle
Woolbright et al. Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA47399B1 (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA44206B1 (fr) Comprimé orodispersible comprenant estetrol
MA30990B1 (fr) Antagonistes du recepteur de progesterone.
MA30504B1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
MA32548B1 (fr) Composition pharmaceutique a base de progesterone micronisee et ses utilisations
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
Roque Bravo et al. Cocaine: an updated overview on chemistry, detection, biokinetics, and pharmacotoxicological aspects including abuse pattern
MA29836B1 (fr) Proteines de fusion avec l'albumine
TN2009000138A1 (fr) Biaryl-ether-urees
MA33057B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan
MA31169B1 (fr) Preparation solide comprenant de l'alogliptine et de la pioglitazone
Goel et al. Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: protection by angiotensin converting enzyme inhibition
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA31471B1 (fr) Formulations d'anticorps
MA27835A1 (fr) Methodes pour le traitement de l'atherosclerose, des dyslipemies et conditions apparentees et compositions pharmaceutiques
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
TNSN00139A1 (fr) Acides phenoxyacetiques substitues
MA31796B1 (fr) Composes organiques